Lipoprotein(a) metabolomic and proteomic features and atherosclerotic cardiovascular disease in young, healthy adults

Brief Title: Lipoprotein(a) metabolomics and proteomics in young, healthy adults

Sascha N. Goonewardena^{1,2*}, Tomasz Jurga³, Donald Lloyd-Jones⁴, Dilna Damodaran¹, Bharat Thyagarajan⁵, David R. Jacobs, Jr.⁶, Supriya Shore¹, Eric J. Brandt^{1,7}, Clary Clish⁸, Kahraman Tanriverdi⁹, Jane E. Freedman⁹, Brian T. Emmer¹⁰, John T. Wilkins¹¹, Ron Do¹², Vera A. Bittner¹³, Robert S. Rosenson¹⁴, Ravi V. Shah⁹, Venkatesh L. Murthy¹

¹Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA

² Division of Cardiovascular Medicine, VA Ann Arbor Health System, Ann Arbor, Michigan, USA.

³ Department of Pharmacy, VA Ann Arbor Health System, Ann Arbor, Michigan, USA

⁴ Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

⁵ Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA

⁶ University of Minnesota School of Public Health, Division of Epidemiology and Community Health, Minneapolis, MN, USA.

⁷ Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan, USA

⁸ Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA

⁹ Vanderbilt Translational and Clinical Research Center, Cardiovascular Division, Vanderbilt University Medical Center, Nashville, TN, USA

¹⁰ Department of Internal Medicine, Division of Hospital Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA

¹¹ Division of Cardiology, Department of Medicine Northwestern, University Feinberg School of Medicine, Chicago, Illinois, USA

¹² The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

¹³ Department of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, USA

¹⁴ Metabolism and Lipids Program, Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York, USA

*Primary contact Information: Sascha N. Goonewardena, MD, University of Michigan Frankel Cardiovascular Center, 1500 East Medical Center Drive, SPC 5853, Ann Arbor, MI 48109-5853. Email: sngoonew@med.umich.edu

ABSTRACT

Background: Elevated lipoprotein (a) [Lp(a)] is associated with a higher risk of atherosclerotic cardiovascular disease (ASCVD) events. Although Lp(a) is a genetically determined risk factor, the metabolomic and proteomic features that may mediate or be associated with this risk are unknown.

Methods: In young, healthy Coronary Artery Risk Development in Young Adults (CARDIA) participants, we defined the relationships between year 7 (Y7) Lp(a) and metabolomic (n=563)/proteomic (n=184) features, derived quantitative Lp(a)-omic scores from these features, and related these quantitative scores to ASCVD phenotypes.

Results: CARDIA participants had a mean age of 32 years at Y7 in this study and a median follow-up of 27.1 years. In the overall cohort (n=3920), Y7 Lp(a) levels were associated prospectively with ASCVD phenotypes at year 25 (Y25), including hs-CRP, coronary artery calcification (CAC), and incident CHD. In the subcohort (n=2290) that had measurements of Lp(a), proteomics, and metabolomics, Y7 Lp(a) levels were associated with distinct proteomic and metabolomic features indicative of immune responses, lipoprotein metabolism, atherogenesis, and arginine/steroid biosynthesis. Using machine learning approaches, Lp(a) metabolomic, proteomic, and transomic quantitative scores were derived. The Y7 Lp(a) transomic score was more strongly associated with Y25 incident CAC (standardized $\beta = 0.29$, p=0.04), hs-CRP (standardized $\beta = 0.18$, p =0.0008), and incident any CHD (standardized $\beta = 0.51$, p = 0.05), than the Y7 Lp(a) concentration itself (no significant associations).

Conclusions: To our knowledge, this is the first study to identify relationships between Lp(a) and associated metabolomic/proteomic features in young, healthy adults and joint associations with ASCVD phenotypes. The multi-omics approaches employed here provide insight into the pathobiology of Lp(a)-driven ASCVD and enable more nuanced mechanistic risk assessment compared with Lp(a) concentrations alone.

Keywords

Inflammation; lipoproteins; thrombosis; atherosclerosis; ASCVD; lipoprotein(a)

Word Count: 4952

Abbreviations

ASCVD: atherosclerotic cardiovascular disease CAC: coronary artery calcification

CARDIA: Coronary Artery Risk Development in Young Adults CVD: cardiovascular disease CHD: coronary heart disease DAMP: damage-associated molecular pattern hs-CRP: high-sensitivity C-reactive protein LDL: low-density lipoprotein Lp(a): Lipoprotein(a) MESA: Multi-Ethnic Study of Atherosclerosis OxPL: oxidized phospholipids PRRs: pattern recognition receptors Y7: year 7

Introduction

Despite major therapeutic advances, atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality worldwide.¹ This is due to a continued high prevalence of traditional risk factors, including a lack of heart-healthy dietary practices, and an aging population.² However, even after accounting for traditional risk factors, significant risk remains. Part of this risk is mediated by elevated levels of lipoprotein(a) [Lp(a)]. Lp(a) is an apolipoprotein B particle that is covalently attached to an apolipoprotein(a) glycoprotein. Elevated concentrations of Lp(a) increase the risk for ASCVD events in persons with and without coronary heart disease (CHD).^{3–5} Observational cohort studies, post hoc analyses of clinical trials, and Mendelian randomization studies suggest an independent, likely causal relationship between elevated Lp(a) levels and ASCVD risk.^{6–9} Although there are currently no approved pharmacological therapies that directly target elevated lipoprotein(a), several therapies are in development that reduce apolipoprotein(a) production by up to 80%–99%.¹⁰

Mechanistically, Lp(a) promotes ASCVD through multiple pathways, including atherogenesis, thrombosis, and inflammation.¹¹ Intriguingly, studies suggest that on a per particle basis, Lp(a) is associated with more atherosclerosis than LDL implying that Lp(a) possesses additional atherogenic properties compared with LDL.¹² Given that a major structural component of Lp(a) is encoded by a gene (LPA) that was duplicated from the plasminogen gene, it has been hypothesized that modulation of fibrinolysis could mediate the effects of Lp(a) on thrombosis.¹³⁻ ¹⁵ However, several studies in murine models and human cohorts have failed to demonstrate a clear effect of Lp(a) on fibrinolysis or venous thromboembolic disease.¹⁶ Several basic and observational studies have demonstrated a relationship between Lp(a) and inflammation.¹⁷ In asymptomatic middle-aged participants in MESA (Multi-Ethnic Study of Atherosclerosis), Lp(a) ASCVD risk and all-cause mortality were only observed in combination with an elevated hs-CRP (>2 mg/L).¹⁸ More recently, a risk factor and context-dependent relationship between Lp(a) and inflammation has emerged.¹⁹ A study by Arnold and colleagues found that high levels of Lp(a) were associated with an increased risk of CHD events, regardless of the level of hs-CRP in individuals without CHD.²⁰ However, in individuals with established CHD, Lp(a) was only associated with recurrent CHD events in those with high hs-CRP levels. Functional evidence linking Lp(a) to inflammation has been revealed in experimental models and clinical studies

demonstrating that Lp(a) is the primary lipoprotein carrier of phosphocholine-containing oxidized phospholipids (OxPL), a damage-associated molecular pattern (DAMP) that can be recognized by pattern recognition receptors (PRRs) on immune and non-immune cells.^{21,22} In total, Lp(a) appears to influence multiple pathways in a context- and subject-specific manner to drive ASCVD.

Although it is appreciated that Lp(a) can work through distinct mechanisms to drive ASCVD, how these mechanisms directly link to heterogeneous ASCVD endpoints has remained elusive. To identify candidate pathways that might mediate the increased risk of ASCVD, we leveraged Lp(a) associated metabolomic and proteomic signatures in conjunction with the longitudinal follow-up of young, healthy adults in CARDIA and identified pathway-specific associations linking Lp(a) with ASCVD phenotypes. Specifically, we employed 563 metabolomic and 184 proteomic features (approximately 1.7 million measurements) in 2299 participants with Lp(a) measurements in the CARDIA study. Using machine learning approaches, we developed Lp(a) quantitative metabolomic and proteomic signatures and related these to ASCVD phenotypes and clinical outcomes. Overall, these studies are the first to derive Lp(a) metabolomic and proteomic quantitative risk assessments and novel mechanistic insights through which Lp(a) could accelerate ASCVD.

Materials and Methods

Study participants and Lp(a) measurements. The CARDIA study is a prospective, observational cohort study of 5115 participants (white and Black, age 18-30 years, recruited in 1985 and 1986 from Birmingham, AL; Chicago, IL; Minneapolis, MN; Oakland, CA). At inception, there were 5115 participants enrolled at ages 18-30 years, balanced on age, education status, and self-reported sex and race. CARDIA participants have undergone in-person examinations at baseline (Year 0: Y0) and at Y2, Y5, Y7, Y10, Y15, Y20, Y25, Y30, and Y35. Retention rates among surviving participants at each in-person examination were 91%, 86%, 81%, 79%, 74%, 72%, 71%, and 67% (during the COVID-19 pandemic), respectively. 1156 individuals were excluded due to missing Y7 Lp(a), 36 were excluded for missing key covariates (age, sex, race, total cholesterol, HDL-C LDL-C, triglycerides, diabetes status, systolic and diastolic blood pressure, use of antihypertensive medications, and smoking status at Y7), and 2 for

incident coronary heart disease before Y7 resulting in an analysis sample of n=3920 (full cohort with Lp(a) measured at Y7) and n=2299 (subcohort with Lp(a) and metabolomics/proteomics at Y7) Participants provided written informed consent, and CARDIA was approved by Institutional Review Boards at participating institutions. Plasma Lp(a) analyses were performed by an ELISA method insensitive to apo[a] size heterogeneity.²³

Metabolite and proteomic profiling. We used plasma samples for metabolite and proteomic profiling. Metabolite profiling in CARDIA from Y7 samples has been previously described.²⁴ In brief, the methods include a C8 reversed-phase liquid chromatography (LC) with positive ion mass spectrometry (MS) for lipid quantification (C8-pos); a C18 reversed-phase LC with negative ion MS (C18-neg) for quantification of fatty and bile acids; a hydrophilic interaction LC with positive ion MS (HILIC-pos) and negative ion MS (HILIC-neg) for cationic and anionic polar metabolites, respectively. For analyses, we included metabolites with missingness of <10% and CV<10%. Metabolite values were natural logarithm transformed to improve normality. We performed targeted proteomics assays (Olink CVD II and CVD III panels, Uppsala, Sweden) on Y7 samples in CARDIA.²⁵ This proximity-extension assay technique generates amplification cycle numbers that are normalized (Olink NPX Manager Software v3.1.1.399) to protein expression levels (NPX) (arbitrary units on log2 scale).

CARDIA Outcomes definitions. Contact is maintained with participants via telephone, mail, or email every 6 months, with annual interim medical history ascertainment. Over the last 5 years, >90% of the surviving cohort members have been directly contacted and follow up for vital status is virtually complete through related contacts and intermittent National Death Index searches. For this study, we evaluated clinical events (incident hard CHD, any CHD, and death from any cause as adjudicated per CARDIA protocol), and subclinical coronary atherosclerosis as measured by Agatston CAC scores on computed tomography at year 15, 20 and 25.²⁶ CAC scores were treated either continuously (after transformation as the natural log transformation of the score plus 1) or dichotomized (as zero or non-zero). Hs-CRP was measured at Y7, year 15, year 20, and year 25. Hard CHD was defined as non-fatal myocardial infarction, non-fatal non-MI acute coronary syndrome, definite fatal MI, and definite or possible fatal CHD. For, "any CHD" coronary revascularization is added to the hard CHD composite of outcome. Time to events was defined from the Y7 examination date with a median follow-up of 27.1 years.

Statistical analysis. We compared continuous and categorical variables across groups using Wilcoxon rank-sum and chi-square tests, respectively. We graphically evaluated distributions and elected to natural log transform Lp(a) to improve normality. Additionally, we converted Lp(a) to a binary variable by dichotomization at 150 nmol/L and used quintiles for further analyses. The high Lp(a) concentration was defined as $\geq 150 \text{ nmol/L}$ (70 mg/dL) based on the inclusion criteria of the Lp(a)HORIZON clinical trial. We used linear, logistic, Cox, and Poisson regression for continuous, binary, time to event, and event rate outcomes, respectively. We scaled key continuous predictors and outcomes to unit variance and zero mean to present standardized beta coefficients. These regressions were performed without adjustment (unadjusted), adjusted for age/sex/race, or fully adjusted (for age, sex, race, total cholesterol, HDL-C LDL-C, triglycerides, diabetes status, systolic and diastolic blood pressure, use of antihypertensive medications, and smoking status [all at Y7]). Event rates for incident hard and any CHD and all-cause mortality across quintiles of Lp(a), LDL-C, and hs-CRP were computed with Poisson regression across each of the three adjustment approaches. Significance was evaluated for individual quintile groups as well as for linear trends across quintiles. We also related Lp(a) continuously, dichotomized at 150 nmol/L or across quintiles with all clinical and subclinical endpoints using linear, logistic, or Cox regression, as appropriate.

For metabolomic and proteomic analyses, we randomly divided the subset of the cohort with measured proteomics and metabolomics into 70% for derivation and 30% for validation samples. We performed linear regression with natural log transformed and standardized Lp(a) as the predictor and each proteomic and metabolomic feature as an outcome variable (also standardized). These were performed as unadjusted, age/sex/race adjusted, and fully adjusted models to derive standardized betas. P-values were adjusted using the Benjamini-Hochberg false discovery rate (FDR) control method within each predictor set and adjustment approach. These relationships were used to identify potentially mechanistically relevant relationships between Lp(a) and candidate effectors.

We also developed signatures of Lp(a) (continuous variable) using Least Absolute Shrinkage and Selection Operator (LASSO) penalized regression using metabolites features alone, proteomics features alone, or both combined as predictors. The LASSO hyperparameter (λ) was optimized with repeated 5-fold cross-validation. The signatures were fit in the (70%) derivation subset and then computed in both the derivation and validation subsets. Omics signatures were then related

to the outcomes using linear, logistic, and Cox regression as above. Models including omics scores and additionally adjusted for Lp(a) were also fit to enable comparison of the scores with measured Lp(a). Statistical analyses were performed in R version 4.3.2 (R Foundation for Statistical Computing, Vienna, Austria), and a type 1 error of 5% (significance level 0.05) was used with type 1 error handling where noted.

Unadjusted metabolites and proteins with regression coefficients significant at a 5% FDR were selected for pathway analysis using MetaboAnalyst 6.0 (https://www.metaboanalyst.ca/) and mapped to both metabolic pathways and gene-only pathways in KEGG database, respectively. A hypergeometric test was used for enrichment analysis and degree centrality was used for topology measure. P-values from metabolites and proteins were combined via Z-test as an integrative enrichment P-value for each pathway. All pathways with an FDR less than 0.001 (in the pathway analysis for cross-sectional or longitudinal data) were selected for result interpretation and visualization.

Resources, data, and code availability. Data have been deposited at the CARDIA Coordinating Center as listed in the key resources table. Access can be obtained directly from the CARDIA Coordinating Center (www.uab.dopm.edu/cardia) and is available as of the date of publication. Accession identifier numbers are listed in the key resources table. This paper does not report the original code. The code here uses standard packages in R studio. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

Results

Characteristics of the CARDIA cohort. Lp(a) and key covariates were measured at year 7 (Y7) in 3920 participants without prior CHD. The demographic and laboratory characteristics of this cohort are shown in **Table 1**. The distribution of age and sex were similar across Lp(a) strata (**Table 1**). As previously described, Lp(a) levels were modestly higher in black compared with white participants.²⁷ Lp(a) itself was only weakly correlated with other Y7 parameters including total cholesterol (R=0.14; p<0.0001), LDL-C (R=0.16; p<0.0001), HDL-C (R=0.05; p=0.004), triglycerides (R=-0.04; p=0.01), and hs-CRP (R=0.11; p<0.0001) (**Supplemental Figure 1**).

Lp(a) is associated with clinical markers of inflammation, atherosclerosis, and CHD events in young, healthy adults. To understand the relationship between Lp(a) concentrations and the

risk of subclinical and clinical ASCVD, we studied participants in CARDIA with a median followup of 27.1 years. We quantified the risk of ASCVD (and associated atherogenic and inflammatory phenotypes) across the spectrum of observed Lp(a) concentrations as well as through Lp(a) quintiles. With respect to atherogenesis and inflammation, Y7 Lp(a) was associated with CAC and hs-CRP (Figure 1 and Supplemental Figure 2). In the model adjusted for age, sex, and race, Lp(a) as a continuous variable was associated with incident hard and any CHD (Figure 1). The incidence of any and hard CHD was 1.82 per 1000 person-years and 1.43 per 1000 person-years in the highest quintile of Lp(a); in contrast, the incidence of any and hard CHD was 1.03 per 1000 person-years and 0.93 per 1000 person-years in the lowest quintile of Lp(a) (Supplemental Figure 3). Interestingly, the Lp(a) quintile analysis showed an inverse association between all-cause mortality in the age, sex, and race-adjusted model (Supplemental Figure 2). This association with mortality was not apparent when Lp(a) was examined using 150 nmol/L cutoff or Lp(a) as a continuous variable, nor was it significant in the unadjusted or fully adjusted models. To contextualize risk gradient across quintiles of Lp(a), we also conducted similar quintile analyses for Y7 LDL cholesterol (LDL-C) and hs-CRP and how these relate to CHD outcomes. With respect to any and hard CHD events, for the highest quintile of LDL-C, the incidence was 3.13 per 1000 person-years and 2.37 per 1000 person-years, respectively (Supplemental Figure 3), as compared to the lowest quintile of LDL-C. For hs-CRP, those in the highest quintile had an incidence of any and hard CHD events of 1.75 per 1000 person-years and 1.5 per 1000 personyears, respectively, more closely approximating the risk of the highest quintile of Lp(a) than LDL-C. In young, healthy adults, Lp(a) levels are associated not only with CHD endpoints, but also with atherogenic and inflammatory phenotypes.

Lp(a) levels in young, healthy adults are associated with distinct metabolic and proteomic features. Although Lp(a) influences ASCVD through multiple mechanisms, significant heterogeneity exists through which these pathological mechanisms contribute to the distinct clinical manifestations of ASCVD. To further illuminate the biological pathways that could underlie the associations between Lp(a) and ASCVD, we measured circulating metabolites and proteins in young adulthood (Y7 CARDIA) and how Y7 Lp(a) levels relate to these molecular features. The characteristics of this CARDIA subcohort (having Y7 Lp(a), metabolomics, and proteomics; N=2299) are shown in **Supplemental Table 1**. 563 metabolomic, and 184 proteomic

features were analyzed in this subcohort. The results of linear, logistic, and Cox models are presented in the **Supplementary Data File** and **Figure 2**. From proteins and metabolites that were significant in single regression analyses (Y7 Lp(a) as the predictor variable), we found pathway annotations for 222 unique metabolites and 57 proteins. **Figure 2** shows a summary of the standardized regression coefficients for regression analyses across prioritized pathways. Pathway analyses identified cytokine-cytokine receptor interaction, lipid and atherosclerosis, arginine and proline metabolism, and steroid biosynthesis pathways which were related to Y7 Lp(a) levels.

Derivation of Lp(a)-associated metabolomic, proteomic, and transomic signatures in young, healthy adults. Using LASSO regression analysis, we derived Lp(a)-quantitative scores comprised of the most significant metabolites and proteins (integration of them both [transomic]) (Figure 3). Not surprisingly, in the validation cohort, the metabolomic, proteomic, and transomic scores were significantly correlated with Y7 Lp(a) levels, from which they were derived, with correlation coefficients of 0.30, 0.25, and 0.30, respectively (Supplemental Figure 4). When examining the specific components of the metabolomic and proteomic scores that drive the association with Y7 Lp(a), several observations are worth noting. With respect to specific metabolites, some of the strongest contributions (both positive and negative) to the Lp(a) metabolic score were C24:1 ceramide, cytosine, and adenosine (Figure 3 and Supplemental Figure 5). For specific proteins, some of the strongest contributions (both positive and negative) to the Lp(a) proteomic score included TFPI, MMP2/12, SCF, LPL, and NT-proBNP, which have all been linked to ASCVD (Figure 3 and Supplemental Figure 5). These findings suggest that metabolic derangements, vascular dysfunction, and immune activation contribute to the Lp(a)-associated molecular instruments, providing insight into the pathobiology through which Lp(a) could underlie and accelerate ASCVD.

Lp(a) derived metabolic and proteomic signatures are more strongly associated with accelerated atherogenesis and inflammation than Lp(a) itself. Because of the complex relationships between Lp(a), pathogenic pathways, and ASCVD clinical and subclinical phenotypes, we leveraged the quantitative Lp(a) omic scores. We assessed how these quantitative scores relate to clinical markers of inflammation (hs-CRP), atherosclerosis (CAC), and CHD

outcomes. Although the Lp(a) omic scores were significantly correlated with Lp(a) levels, the correlation was modest, allowing for the possibility that the scores themselves may provide additional insights into Lp(a)-mediated ASCVD and ASCVD risk. In brief, we employed a statistical learning approach in which atherogenic (CAC), inflammatory (hs-CRP), and ASCVD events were modeled as a function of the Y7 Lp(a) metabolomic, proteomic, and transomic quantitative scores (Figure 4 and Supplemental Figure 6). Because of the smaller number of participants in our CARDIA-omics subcohort (n=2299), not surprisingly, the significance of the associations between Lp(a) and clinical and subclinical ASCVD endpoints were muted compared with the larger cohort (n=3920). In this young, healthy subcohort, measured Lp(a) itself had minimal associations with ASCVD endpoints compared with Lp(a)-omics scores. For example, when comparing the Y7 Lp(a) transomic score to Y7 Lp(a) in the adjusted model, Y7 Lp(a) had minimal significant associations with ASCVD phenotypes. Specifically, the Y7 Lp(a) transomic score was more strongly associated with Y25 incident CAC (standardized $\beta = 0.29$, p=0.04), hs-CRP (standardized $\beta = 0.18$, p =0.0008), and incident any CHD (standardized $\beta = 0.51$, p = 0.05), than Y7 Lp(a) itself (no significant associations) (Figure 4 and Supplemental data). Even with a reduced sample size in the subcohort, each of the Lp(a) -omic scores were significantly associated with ASCVD phenotypes in contrast with Lp(a) levels themselves, thereby providing provocative insight not only into the pathobiology of Lp(a) mediated ASCVD but also to ASCVD risk.

Discussion

In this study of young, healthy adults in CARDIA, we examined the relationships between Lp(a) levels and metabolomic/proteomic features and how these related to the development of subclinical and clinical ASCVD phenotypes. Our major findings are that: 1) Lp(a) levels in a young, healthy cohort are associated with accelerated atherogenesis, inflammation, and premature CHD endpoints; 2) Lp(a) levels are associated with specific metabolomic and proteomic features; 3) quantitative Lp(a) derived metabolomic and proteomic scores are associated with accelerated inflammation (hs-CRP), atherogenesis (CAC), and ASCVD phenotypes; and 4) the quantitative Lp(a) derived metabolomic and proteomic scores are more strongly related to these phenotypes than Lp(a) itself (from which these quantitative scores were derived). These findings are the first to link Lp(a) to metabolomic/proteomic features and to use the features to understand Lp(a)

associated subclinical and clinical ASCVD phenotypes, providing potential mechanistic insight into the pathways through which Lp(a) accelerates ASCVD.

Extending on prior findings from higher-risk populations, we found that in young, healthy individuals, Lp(a) is associated with subclinical ASCVD phenotypes and CHD risk. Specifically, Lp(a) was associated not just with incident CHD but also with atherogenic phenotypes (e.g., year 25 CAC) and evidence of heightened inflammation (e.g., hs-CRP at year 25). A study of middleaged participants in the UK Biobank also demonstrated that higher Lp(a) concentrations were associated with an increased risk of ASCVD events.²⁷ This differential risk (between participants with a high and low Lp(a)) was more pronounced in individuals without a prior history of ASCVD. Additionally, a study of participants from the UK Biobank, as well as additional analyses of participants from the FOURIER and SAVOR-TIMI 53 trials, showed that higher Lp(a) is associated with a higher risk of ASCVD in both primary and secondary prevention populations regardless of baseline hs-CRP.²⁸ One unique aspect of our study is the evaluation of a younger patient population with less cardiovascular risks, namely less hypertension, diabetes, and lower baseline LDL-C when compared to MESA, ARIC, and the UK Biobank.^{18,29-31} In higher-risk populations, LDL-C and hs-CRP have been associated with ASCVD phenotypes. Consistent with these findings, we also found that LDL-C and hs-CRP are associated with CHD and Lp(a) risk is more similar to hs-CRP with respect to the magnitude of ASCVD risk. These findings carry major implications given that Lp(a) is less dynamic than other markers of ASCVD risk. For example, markers such as LDL-C respond to lifestyle modifications and drug therapy, while Lp(a) remains largely unchanged.³² Intriguingly, perhaps because of the lower ASCVD risk of the CARDIA cohort, there was a trend towards increased mortality in the lowest quintile of Lp(a), which is discordant from ASCVD events. The total number of deaths overall is low, and the magnitude and significance were not dependent on Lp(a) levels. Future studies are needed to verify this unexplained finding which could be due to competing risk or simply due to chance. Overall, our results extend the ASCVD Lp(a) findings from other observation cohorts to a younger, lower-risk population, connecting Lp(a) to markers of inflammation and atherogenesis and ASCVD phenotypes.

Clinical trials with RNA-based therapeutics that reduce Lp(a) levels by 80-99% are ongoing.¹⁰ They will directly test the "Lp(a) hypothesis" that profound reductions in Lp(a) levels will reduce the risk of ASCVD. To complement these clinical outcomes trials, understanding the underlying mechanisms through which Lp(a) accelerates ASCVD and how individual-specific risk influences these mechanisms will not only help in identifying patients most likely to benefit from these therapeutics but also in expanding our knowledge of ASCVD itself. Our metabolomic and proteomic findings reinforce known and reveal unknown relationships between Lp(a) and pathways that underlie ASCVD. Among the correlates of Lp(a) in our single regression analyses, we identified several markers of vascular dysfunction (RAGE, PSGL1) and inflammation (MERTK, MCP1), all of which have been associated with ASCVD.³³⁻³⁶ With respect to metabolites, the links to Lp(a) in this young, healthy cohort were strong. For example, C9 carnitine and SM(d18:1/24:1) were associated with Y7 Lp(a) levels, and both have been linked to ASCVD and ASCVD risk factors, suggesting that Lp(a) could be modulating metabolic risk upstream of these features.^{37,38} From a pathway perspective, the metabolomic and proteomic features revealed both known and unknown pathways through which Lp(a) could be driving ASCVD. The immunemediated pathways (e.g. cytokine-cytokine receptor interaction, chemokine signaling) jointly implicated from the metabolomic and proteomic have clear links to ASCVD.³⁹ Arginine biosynthesis is a provocative pathway associated with Lp(a) metabolomic features and has clear links to ASCVD.⁴⁰ As alluded to earlier, the multi-omic approaches not only provide insight into quantitative, patient-specific risk but also provide insight into the mechanisms that give rise to ASCVD heterogeneity and the multitude of pathways that could accelerate ASCVD.

Using metabolic and proteomic features, we created quantitative Lp(a) metabolomic, proteomic, and transomic scores and related these quantitative scores to ASCVD phenotypes. ASCVD heterogeneity is a manifestation of the complex convergent processes that accelerate ASCVD. With respect to the pathobiology of ASCVD, Lp(a) has multifarious properties that increase atherogenesis, thrombosis, and inflammation, all of which can accelerate ASCVD and trigger atherothrombotic events. Evidence of this can be seen in our data, in that Lp(a) is associated with pathway-specific molecular features and clinical markers of inflammation (hs-CRP) and atherogenesis (CAC). The individual Lp(a) proteomic and metabolomic features themselves had minimal relationships to ASCVD phenotypes. However, the machine learning quantitative scores,

a composite of the individual metabolomic/proteomic features, were not only associated with ASCVD phenotypes, but these associations were stronger than the level of Lp(a) itself.

Study Limitations

Several limitations of our study warrant consideration. First, although our clinical assay for Lp(a) concentration employs an isoform-insensitive immunoassay, we did not have information on oxidized phospholipids content that may more precisely link metabolomic/proteomic features to distinct Lp(a) properties. Additionally, our design was a split-set design, as the ASCVD risk factor distribution (e.g., age and diabetes) and metabolite/protein coverage are unique to this cohort. Although the uniqueness of our cohort and data set captures an understudied early timepoint in Lp(a) driven ASCVD risk, these findings must be validated in other populations with a higher prevalence of ASCVD risk factors. Finally, the observational nature of our study precludes any strict determinations of causality with respect to Lp(a) pathobiology; however, we believe that our findings are hypothesis generating and can help inform future mechanistic studies.

Conclusions

In summary, we integrated metabolomics and proteomics with Lp(a) levels in young, healthy adults to reveal molecular mediators through which Lp(a) may drive ASCVD. More broadly, the metabolomic and proteomic approaches employed here provide insight into ASCVD heterogeneity and how patient-specific exposures interact with Lp(a) during the genesis of ASCVD. This study adds further evidence linking inflammation and atherogenesis in ASCVD and furthers our understanding whereby Lp(a) can be used to identify individuals at risk for ASCVD.

AUTHOR CONTRIBUTIONS

Acknowledgments: Although not directly involved in the conduct of this study, we thank the volunteers, patients, and staff caring for them for their contribution and commitment to clinical research.

FUNDING and DECLARATION OF INTERESTS

Dr. Goonewardena is supported by VA MERIT grant 1101CX002560), Taubman Medical Research Institute (Wolfe Scholarship). Dr. Murthy owns stock or stock options in General Electric, Cardinal Health, Ionetix, Boston Scientific, Merck, Eli Lilly, Johnson and Johnson, and

Pfizer. He has received research grants and consulting fees from Siemens Medical Imaging. He has served on medical advisory boards for Ionetix. Dr. Murthy and Dr. R. Shah are supported in part by grants from the National Institute of Diabetes, Digestive, and Kidney Diseases (U01DK123013-03); National Institute on Aging (R01 AG059729); National Heart, Lung and Blood Institute (R01 HL136685); and an American Heart Association Strategically Focused Research Network grant in Cardiometabolic Disease (funded proteomics in CARDIA). Dr. Shah has served for a consultant for Amgen and Cytokinetics. Dr. Shah is a co-inventor on a patent for ex-RNAs signatures of cardiac remodeling and a pending patent on proteomic signatures of fitness and lung and liver diseases. Dr. Brandt reports research funding from the National Institutes of Health (K23MD017253) and the Blue Cross Blue Shield of Michigan Foundation. He has received consulting fees from New Amsterdam Pharmaceuticals. Dr. Emmer was supported by the National Institutes of Health R01-HL167733 and the A. Alfred Taubman Medical Research Institute. Dr Do is supported by the National Institute of General Medical Sciences of the National Institutes of Health (NIH) (R35-GM124836). Dr. Do reports being a scientific cofounder, consultant, and equity holder (pending) for Pensieve Health and a consultant for Variant Bio, all unrelated to this work. Dr. Bittner reports research funding to her institution from NHLBI through a sub-contract from Wake Forest University, Amgen, Dalcor, Esperion, Novartis, and Sanofi and Regeneron. She serves on DSMBs for NIH-NIA, Eli Lilly, and Verve Therapeutics and has received honoraria from the American College of Cardiology, American Heart Association, National Lipid Association and New Amsterdam Pharma. Dr. Rosenson reports research funding to his institution from Amgen, Arrowhead, Eli Lilly, Merck, NIH, Novartis, Novo Nordisk, Regeneron, and 89Bio , consulting fees from Amgen, Avilar, CRISPER Therapeutics, Eli Lilly, Lipigon, New Amsterdam, Novartis, Precision Biosciences, Regeneron, UltraGenyx, Verve Therapeutics, nonpromotional honoraria from Meda Pharma, royalties from Wolters Kluwer (UpToDate), and stock holding in MediMergent, LLC. He reports patent applications on: Methods and systems for biocellular marker detection and diagnosis using a microfluidic profiling device. EFS ID: 32278349. Application No. (PCT/US2019/026364) (provisional); Compositions and methods relating to the identification and treatment of immunothrombotic conditions. New International Application No. (PCT/US2021/63104926); and quantification of Lp(a) vs. non-Lp(a) apoB concentration: development of a novel validated equation (PCT/US2021/63248837). The Coronary Artery Risk Development in Young Adults Study (CARDIA) is conducted and

supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the University of Alabama at Birmingham (75N92023D00002 & 75N92023D00005), Northwestern University (75N92023D00004), University of Minnesota (75N92023D00006), and Kaiser Foundation Research Institute (75N92023D00003). This manuscript has been reviewed by CARDIA for scientific content.

Table 1. Demographic and laboratory characteristics of CARDIA Lp(a) sample at Year 7, overall and stratified by Lp(a) level. The present study analyzes 3920 individuals with Lp(a) levels measured at Year 7 and complete assessment of key covariates (age, sex, race, diabetes, lipids, blood pressure, BMI, and smoking) and without CHD before year 7.

			Plasma Lp(a) <	Plasma $Lp(a) \ge$	
Characteristic	N	Overall, N=3.920	150 nmol/L, N = 3.377	150 nmol/L, N = 543	p- value
Age (v)	3.920	32.0 (29.0, 35.0)	32.0 (29.0, 35.0)	32.0 (29.0, 35.0)	0.9
Male Sex	3,920	1,767 (45%)	1,528 (45%)	239 (44%)	0.6
Race	3,920				< 0.001
Black		1,884 (48%)	1,513 (45%)	371 (68%)	
White		2,036 (52%)	1,864 (55%)	172 (32%)	
BMI (kg/m2)	3,844	25.4 (22.6, 29.5)	25.3 (22.5, 29.2)	25.9 (23.0, 30.3)	0.008
Total Plasma Cholesterol (mg/dl)	3,920	174 (153, 198)	172 (152, 195)	185 (166, 208)	< 0.001
HDL Cholesterol (mg/dl)	3,920	50 (42, 60)	50 (42, 60)	51 (44, 61)	0.028
LDL Cholesterol (mg/dl)	3,920	105 (85, 127)	102 (84, 125)	117 (97, 137)	< 0.001
Triglycerides (mg/dl)	3,920	67 (47, 101)	67 (47, 102)	66 (47, 97)	0.4
Diabetes	3,920	129 (3.3%)	108 (3.2%)	21 (3.9%)	0.4
Systolic BP (mmHg)	3,920	107 (100, 115)	107 (100, 115)	108 (102, 116)	0.048
Diastolic BP (mmHg)	3,920	69 (63, 75)	68 (63, 75)	69 (62, 76)	0.5
BP Medication Use	3,920	72 (1.8%)	58 (1.7%)	14 (2.6%)	0.2
Smoking	3,920				0.017
never		2,264 (58%)	1,958 (58%)	306 (56%)	
former		621 (16%)	551 (16%)	70 (13%)	
current		1,035 (26%)	868 (26%)	167 (31%)	
Glucose (mg/dl)	3,900	90 (85, 96)	89 (85, 95)	90 (86, 96)	0.046
Y7 CRP (ug/ml)	3,831	1.1 (0.5, 3.2)	1.1 (0.5, 3.1)	1.4 (0.6, 3.5)	0.002
Y15 CRP (ug/ml)	3,222	1.4 (0.6, 3.7)	1.3 (0.6, 3.5)	1.9 (0.7, 4.8)	< 0.001
Y20 hs-CRP (ug/ml)	3,068	1.12 (0.48, 3.05)	1.09 (0.47, 2.90)	1.37 (0.58, 3.83)	< 0.001
Y25 hs-CRP (ug/ml)	3,027	1.4 (0.6, 3.4)	1.3 (0.6, 3.3)	1.7 (0.7, 4.4)	< 0.001
Plasma Lp(a) (nmol/L)	3,920	45 (14, 104)	33 (12, 76)	196 (167, 233)	< 0.001
Y15 CAC>0	2,732	299 (11%)	254 (11%)	45 (13%)	0.2
Y20 CAC>0	2,766	564 (17%)	477 (17%)	87 (21%)	0.081
Y25 CAC>0	2,782	904 (27%)	752 (25%)	152 (33%)	0.003
Incident Any CHD	3,920	145 (3.7%)	118 (3.5%)	27 (5.0%)	0.09
Incident Hard CHD	3,920	118 (3.0%)	96 (2.8%)	22 (4.1%)	0.13



Figure Legends



Figure 1. Y7 Lp(a) levels in young, healthy adults are associated with inflammatory and atherogenic phenotypes as well as CHD. Heatmap of standardized regression coefficients from models relating Y7 Lp(a) variables (quintiles, 150 nmol/L threshold, and as a continuous variable) to CAC, hs-CRP, and CHD endpoints (outcome variable). Models are adjusted for age, sex, and race. Values for regression coefficient directionality (color), magnitude (color gradient), and statistical significance (color of circle) are depicted in figure legend.

В



Pathways (KEGG and SMPD)	Total	Expected	Hits	Raw p	Holm adjust p value	FDR	Impact
Cytokine-cytokine receptor							
interaction	294	2.1244	20	1.42E-14	4.72E-12	4.72E-12	0.08545
Viral protein interaction with							
cytokine and cytokine receptor	100	0.72259	13	2.34E-13	7.74E-11	3.88E-11	0.11842
Caffeine metabolism	27	0.1951	5	1.24E-06	0.0004083	0.000137	0.13333
Vitamin digestion and							
absorption	63	0.45523	6	5.79E-06	0.001898	0.000427	0.018349
Arginine biosynthesis	44	0.31794	5	1.52E-05	0.0049434	0.000837	0.31429
Chemokine signaling pathway	194	1.4018	7	0.000493	0.16031	0.022923	0.015625

Figure 2. Lp(a) as a predictor of metabolomic and proteomic features. 222 unique metabolites and 57 proteomic features were selected using single regression based on FDR p-value <0.05. A) The dot plot of pathway topology result, where the X-axis shows the pathway impact score, and Y-axis are $-\log 10(p)$ values. The size of the dot reflects the enrichment ratio, and the color reflects the level of significance. B) Top 6 significant pathways from both 85 KEGG mapped metabolites and 57 significant protein features.



Figure 3. LASSO derived Lp(a) metabolomic, proteomic, and transomic scores and individual metabolomic/proteomic feature contributions. Standardized regression coefficients for metabolites and proteins are depicted as bars with the length of the bar proportionate to the

weight, red color for negative weights, and blue for positive weights. Bars are grouped based on the metabolomic or proteomic platform used.



Figure 4. Lp(a) omics scores compared with measured Lp(a) as predictors of clinical and subclinical ASCVD endpoints. Heatmap depicting standardized beta relating omics scores for Lp(a) and measured Lp(a) to coronary artery calcification, high-sensitivity CRP, and outcomes using linear, logistic, and Cox regression adjusted for age, sex, and race. Results are grouped for the metabolomics score, proteomics score, and transomic score. Within these groups, regressions

were separately performed in the score derivation set and score validation set and across both sets pooled (labeled All). Regressions were performed with measured Lp(a), and an omics score in the same model as predictors. Values for regression coefficient directionality (color), magnitude (color gradient), and statistical significance (color of circle) are depicted in figure legend.

References

- 1. Martin SS, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation 2024:CIR.00000000001209. doi:10.1161/CIR.00000000001209.
- 2. Dhindsa DS, Sandesara PB, Shapiro MD, Wong ND. The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. Front Cardiovasc Med 2020;7:88. doi:10.3389/fcvm.2020.00088.
- 3. Colantonio LD, Goonewardena SN, Wang Z, Jackson EA, Farkouh ME, Li M, et al. Incident CHD and ischemic stroke associated with lipoprotein(a) by levels of Factor VIII and inflammation. J Clin Lipidol 2023;17:529–537. doi:10.1016/j.jacl.2023.06.001.
- 4. O'Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial. Circulation 2019;139:1483–1492. doi:10.1161/CIRCULATIONAHA.118.037184.
- 5. Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, et al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. J Am Coll Cardiol 2020;75:133–144. doi:10.1016/j.jacc.2019.10.057.
- 6. Kamstrup PR, Benn M, Tybjærg-Hansen A, Nordestgaard BG. Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population: The Copenhagen City Heart Study. Circulation 2008;117:176–184. doi:10.1161/CIRCULATIONAHA.107.715698.
- Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, et al. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. JAMA Cardiol 2018;3:619. doi:10.1001/jamacardio.2018.1470.
- Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, et al. Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease. N Engl J Med 2009;361:2518–2528. doi:10.1056/NEJMoa0902604.
- 9. Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality. JAMA 2009;302:412. doi:10.1001/jama.2009.1063.
- Malick WA, Goonewardena SN, Koenig W, Rosenson RS. Clinical Trial Design for Lipoprotein(a)-Lowering Therapies. J Am Coll Cardiol 2023;81:1633–1645. doi:10.1016/j.jacc.2023.02.033.
- 11. Rosenson RS, Goonewardena SN. The Residual Risk Odyssey: From LDL to Lp(a). J Am Coll Cardiol 2021;78:434–436. doi:10.1016/j.jacc.2021.04.103.
- 12. Björnson E, Adiels M, Taskinen M-R, Burgess S, Chapman MJ, Packard CJ, et al. Lipoprotein(a) Is Markedly More Atherogenic Than LDL. J Am Coll Cardiol 2024;83:385– 395. doi:10.1016/j.jacc.2023.10.039.

- 13. Schwartz GG, Steg PG, Szarek M, Bittner VA, Diaz R, Goodman SG, et al. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. Circulation 2020;141:1608–1617. doi:10.1161/CIRCULATIONAHA.120.046524.
- 14. Simon DI, Fless GM, Scanu AM, Loscalzo J. Tissue-type plasminogen activator binds to and is inhibited by surface-bound lipoprotein(a) and low-density lipoprotein. Biochemistry 1991;30:6671–6677. doi:10.1021/bi00241a006.
- 15. Palabrica TM, Liu AC, Aronovitz MJ, Furie B, Lawn RM, Furie BC. Antifibrinolytic activity of apolipoprotein(a) in vivo: Human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nat Med 1995;1:256–259. doi:10.1038/nm0395-256.
- 16. Helgadottir A, Gretarsdottir S, Thorleifsson G, Holm H, Patel RS, Gudnason T, et al. Apolipoprotein(a) Genetic Sequence Variants Associated With Systemic Atherosclerosis and Coronary Atherosclerotic Burden But Not With Venous Thromboembolism. J Am Coll Cardiol 2012;60:722–729. doi:10.1016/j.jacc.2012.01.078.
- 17. Tsimikas S, Duff GW, Berger PB, Rogus J, Huttner K, Clopton P, et al. Pro-Inflammatory Interleukin-1 Genotypes Potentiate the Risk of Coronary Artery Disease and Cardiovascular Events Mediated by Oxidized Phospholipids and Lipoprotein(a). J Am Coll Cardiol 2014;63:1724–1734. doi:10.1016/j.jacc.2013.12.030.
- Zhang W, Speiser JL, Ye F, Tsai MY, Cainzos-Achirica M, Nasir K, et al. High-Sensitivity C-Reactive Protein Modifies the Cardiovascular Risk of Lipoprotein(a). J Am Coll Cardiol 2021;78:1083–1094. doi:10.1016/j.jacc.2021.07.016.
- 19. Thomas PE, Vedel-Krogh S, Kamstrup PR, Nordestgaard BG. Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein. Eur Heart J 2023;44:1449–1460. doi:10.1093/eurheartj/ehad055.
- 20. Arnold N, Blaum C, Goßling A, Brunner FJ, Bay B, Ferrario MM, et al. C-reactive protein modifies lipoprotein(a)-related risk for coronary heart disease: the BiomarCaRE project. Eur Heart J 2024:ehad867. doi:10.1093/eurheartj/ehad867.
- 21. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, et al. Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease. N Engl J Med 2005;353:46–57. doi:10.1056/NEJMoa043175.
- 22. Miller YI, Choi S-H, Wiesner P, Fang L, Harkewicz R, Hartvigsen K, et al. Oxidation-Specific Epitopes Are Danger-Associated Molecular Patterns Recognized by Pattern Recognition Receptors of Innate Immunity. Circ Res 2011;108:235–248. doi:10.1161/CIRCRESAHA.110.223875.
- 23. Marcovina SM, Albers JJ, Wijsman E, Zhang Z, Chapman NH, Kennedy H. Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. J Lipid Res 1996;37:2569–2585.
- 24. Murthy VL, Nayor M, Carnethon M, Reis JP, Lloyd-Jones D, Allen NB, et al. Circulating metabolite profile in young adulthood identifies long-term diabetes susceptibility: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Diabetologia 2022;65:657–674. doi:10.1007/s00125-021-05641-x.
- 25. Shah RV, Zhong J, Massier L, Tanriverdi K, Hwang S-J, Haessler J, et al. Targeted Proteomics Reveals Functional Targets for Early Diabetes Susceptibility in Young Adults. Circ Genomic Precis Med 2024;17. doi:10.1161/CIRCGEN.123.004192.

- 26. Carr JJ, Jacobs DR, Terry JG, Shay CM, Sidney S, Liu K, et al. Association of Coronary Artery Calcium in Adults Aged 32 to 46 Years With Incident Coronary Heart Disease and Death. JAMA Cardiol 2017;2:391. doi:10.1001/jamacardio.2016.5493.
- 27. Patel AP, Wang M, Pirruccello JP, Ellinor PT, Ng K, Kathiresan S, et al. Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank. Arterioscler Thromb Vasc Biol 2020. doi:10.1161/ATVBAHA.120.315291.
- 28. Small AM, Pournamdari A, Melloni GEM, Scirica BM, Bhatt DL, Raz I, et al. Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations. JAMA Cardiol 2024. doi:10.1001/jamacardio.2023.5605.
- 29. Trinder M, Uddin MM, Finneran P, Aragam KG, Natarajan P. Clinical Utility of Lipoprotein(a) and *LPA* Genetic Risk Score in Risk Prediction of Incident Atherosclerotic Cardiovascular Disease. JAMA Cardiol 2021;6:287. doi:10.1001/jamacardio.2020.5398.
- 30. Lloyd-Jones DM, Lewis CE, Schreiner PJ, Shikany JM, Sidney S, Reis JP. The Coronary Artery Risk Development In Young Adults (CARDIA) Study. J Am Coll Cardiol 2021;78:260–277. doi:10.1016/j.jacc.2021.05.022.
- 31. Saeed A, Sun W, Agarwala A, Virani SS, Nambi V, Coresh J, et al. Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study. Atherosclerosis 2019;282:52–56. doi:10.1016/j.atherosclerosis.2018.12.022.
- 32. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31:2844–2853. doi:10.1093/eurheartj/ehq386.
- 33. Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999;103:773–778. doi:10.1172/JCI5624.
- 34. Chaudhuri J, Bains Y, Guha S, Kahn A, Hall D, Bose N, et al. The Role of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and Causality. Cell Metab 2018;28:337–352. doi:10.1016/j.cmet.2018.08.014.
- 35. Nurmohamed NS, Belo Pereira JP, Hoogeveen RM, Kroon J, Kraaijenhof JM, Waissi F, et al. Targeted proteomics improves cardiovascular risk prediction in secondary prevention. Eur Heart J 2022;43:1569–1577. doi:10.1093/eurheartj/ehac055.
- 36. Scott RS, McMahon EJ, Pop SM, Reap EA, Caricchio R, Cohen PL, et al. Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 2001;411:207–211. doi:10.1038/35075603.
- 37. Kikas P, Democritus University of Thrace, Alexandroupolis, Greece, Chalikias G, Democritus University of Thrace, Alexandroupolis, Greece. Cardiovascular Implications of Sphingomyelin Presence in Biological Membranes. Eur Cardiol Rev 2018;13:42. doi:10.15420/ecr.2017:20:3.
- 38. Dambrova M, Makrecka-Kuka M, Kuka J, Vilskersts R, Nordberg D, Attwood MM, et al. Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials. Pharmacol Rev 2022;74:506–551. doi:10.1124/pharmrev.121.000408.
- 39. Libby P. The changing landscape of atherosclerosis. Nature 2021;592:524–533. doi:10.1038/s41586-021-03392-8.

40. Tang WHW, Wang Z, Cho L, Brennan DM, Hazen SL. Diminished Global Arginine Bioavailability and Increased Arginine Catabolism as Metabolic Profile of Increased Cardiovascular Risk. J Am Coll Cardiol 2009;53:2061–2067. doi:10.1016/j.jacc.2009.02.036.